The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion

被引:94
作者
Lansberg, Maarten G. [1 ]
Thijs, Vincent N. [2 ]
Bammer, Roland [1 ]
Olivot, Jean-Marc [1 ]
Marks, Michael P. [1 ]
Wechsler, Lawrence R. [3 ]
Kemp, Stephanie [1 ]
Albers, Gregory W. [1 ]
机构
[1] Stanford Univ, Med Ctr, Stanford Stroke Ctr, Palo Alto, CA 94304 USA
[2] Katholieke Univ Leuven Hosp, Dept Neurol, Louvain, Belgium
[3] Univ Pittsburgh, Med Ctr, Stroke Inst, Pittsburgh, PA USA
关键词
MRI; stroke; thrombolysis;
D O I
10.1161/STROKEAHA.107.508572
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-The aim of this exploratory analysis was to evaluate if a combination of MR angiography (MRA) and diffusion-weighted imaging (DWI) selection criteria can be used to identify patients with acute stroke who are likely to benefit from early reperfusion. Methods-Data from DEFUSE, a study of 74 patients with stroke who received intravenous tissue plasminogen activator in the 3- to 6-hour time window and underwent MRIs before and approximately 4 hours after treatment were analyzed. The MRA-DWI mismatch model was defined as (1) a DWI lesion volume less than 25 mL in patients with a proximal vessel occlusion; or (2) a DWI lesion volume less than 15 mL in patients with proximal vessel stenosis or an abnormal finding of a distal vessel. Favorable clinical response was defined as an improvement on the National Institutes of Health Stroke Scale score of at least 8 points between baseline and 30 days or a National Institutes of Health Stroke Scale score <= 1 at 30 days. Results-Twenty-seven of 62 patients (44%) had an MRA-DWI mismatch. There was a differential response to early reperfusion based on MRA-DWI mismatch status. Reperfusion was associated with an increased rate of a favorable clinical response in patients with an MRA-DWI mismatch (OR, 12.5; 95% CI, 1.8 to 83.9) and a lower rate in patients without mismatch (OR, 0.2; 95% CI, 0.0 to 0.8). Conclusions-The MRA-DWI mismatch model appears to identify patients with stroke who are likely to benefit from reperfusion therapy administered in the 3- to 6-hour time window after symptom onset. The criteria established for the MRA-DWI mismatch model in this study require validation in an independent cohort.
引用
收藏
页码:2491 / 2496
页数:6
相关论文
共 28 条
[1]   Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study [J].
Albers, Gregory W. ;
Thijs, Vincent N. ;
Wechsle, Lawrence ;
Kemp, Stephanie ;
Schlaug, Gottfried ;
Skalabrin, Elaine ;
Bammer, Roland ;
Kakuda, Wataru ;
Lansberg, Maarten G. ;
Shuaib, Ashfaq ;
Coplin, William ;
Hamilton, Scott ;
Moseley, Michael ;
Marks, Michael P. .
ANNALS OF NEUROLOGY, 2006, 60 (05) :508-517
[2]   Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI [J].
Barber, PA ;
Darby, DG ;
Desmond, PM ;
Yang, Q ;
Gerraty, RP ;
Jolley, D ;
Donnan, GA ;
Tress, BM ;
Davis, SM .
NEUROLOGY, 1998, 51 (02) :418-426
[3]   Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: Retrospective study of a renal replacement therapy cohort [J].
Collidge, Tara Anne ;
Thomson, Peter Campbell ;
Mark, Patrick Barry ;
Traynor, James Phillip ;
Jardine, Alan George ;
Morris, Scott Thomas William ;
Simpson, Keith ;
Roditi, Giles Hannibal .
RADIOLOGY, 2007, 245 (01) :168-175
[4]   The clinical-DWI mismatch -: A new diagnostic approach to the brain tissue at risk of infarction [J].
Dávalos, A ;
Blanco, M ;
Pedraza, S ;
Leira, R ;
Castellanos, M ;
Pumar, JM ;
Silva, Y ;
Serena, J ;
Castillo, J .
NEUROLOGY, 2004, 62 (12) :2187-2192
[5]   Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging [J].
Davis, SM ;
Donnan, GA ;
Butcher, KS ;
Parsons, M .
CURRENT OPINION IN NEUROLOGY, 2005, 18 (01) :47-52
[6]   Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial [J].
Furlan, A ;
Higashida, R ;
Wechsler, L ;
Gent, M ;
Rowley, H ;
Kase, C ;
Pessin, M ;
Ahuja, A ;
Callahan, F ;
Clark, WM ;
Silver, F ;
Rivera, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2003-2011
[7]   Dose escalation of desmoteplase for acute ischemic stroke (DEDAS) - Evidence of safety and efficacy 3 to 9 hours after stroke onset [J].
Furlan, AJ ;
Eyding, D ;
Albers, GW ;
Al-Rawi, Y ;
Lees, KR ;
Rowley, HA ;
Sachara, C ;
Soehngen, M ;
Warach, S ;
Hacke, W .
STROKE, 2006, 37 (05) :1227-1231
[8]   The Desmoteplase In Acute Ischemic Stroke Trial (DIAS) - A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase [J].
Hacke, W ;
Albers, G ;
Al-Rawi, Y ;
Bogousslavsky, J ;
Davalos, A ;
Eliasziw, M ;
Fischer, M ;
Furlan, A ;
Kaste, M ;
Lees, KR ;
Soehngen, M ;
Warach, S .
STROKE, 2005, 36 (01) :66-73
[9]  
Hacke W, 2004, LANCET, V363, P768
[10]   Validation of an acute ischemic stroke model - Does diffusion-weighted imaging lesion volume offer a clinically significant improvement in prediction of outcome? [J].
Johnston, Karen C. ;
Wagner, Douglas P. ;
Wang, Xin-Qun ;
Newman, George C. ;
Thijs, Vincent ;
Sen, Souvik ;
Warach, Steven .
STROKE, 2007, 38 (06) :1820-1825